Tarun Mandal to Cell Line, Tumor
This is a "connection" page, showing publications Tarun Mandal has written about Cell Line, Tumor.
Connection Strength
0.370
-
Kundu AK, Chandra PK, Hazari S, Ledet G, Pramar YV, Dash S, Mandal TK. Stability of lyophilized siRNA nanosome formulations. Int J Pharm. 2012 Feb 28; 423(2):525-34.
Score: 0.063
-
Pamujula S, Hazari S, Bolden G, Graves RA, Chinta DD, Dash S, Kishore V, Mandal TK. Cellular delivery of PEGylated PLGA nanoparticles. J Pharm Pharmacol. 2012 Jan; 64(1):61-7.
Score: 0.063
-
Kundu AK, Chandra PK, Hazari S, Pramar YV, Dash S, Mandal TK. Development and optimization of nanosomal formulations for siRNA delivery to the liver. Eur J Pharm Biopharm. 2012 Feb; 80(2):257-67.
Score: 0.063
-
Kundu AK, Hazari S, Chinta DD, Pramar YV, Dash S, Mandal TK. Development of nanosomes using high-pressure homogenization for gene therapy. J Pharm Pharmacol. 2010 Sep; 62(9):1103-11.
Score: 0.058
-
Pamujula S, Hazari S, Bolden G, Graves RA, Chinta DM, Dash S, Kishore V, Mandal TK. Preparation and in-vitro/in-vivo evaluation of surface-modified poly (lactide-co-glycolide) fluorescent nanoparticles. J Pharm Pharmacol. 2010 Apr; 62(4):422-9.
Score: 0.056
-
Chowdhury N, Chaudhry S, Hall N, Olverson G, Zhang QJ, Mandal T, Dash S, Kundu A. Targeted Delivery of Doxorubicin Liposomes for Her-2+ Breast Cancer Treatment. AAPS PharmSciTech. 2020 Jul 21; 21(6):202.
Score: 0.029
-
Powell D, Chandra S, Dodson K, Shaheen F, Wiltz K, Ireland S, Syed M, Dash S, Wiese T, Mandal T, Kundu A. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer. Eur J Pharm Biopharm. 2017 May; 114:108-118.
Score: 0.023
-
Chandra PK, Kundu AK, Hazari S, Chandra S, Bao L, Ooms T, Morris GF, Wu T, Mandal TK, Dash S. Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes. Mol Ther. 2012 Sep; 20(9):1724-36.
Score: 0.016